Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic Dermatitis

ConclusionsThese data suggest that dupilumab treatment in infants and children younger than 6 years with AD does not increase overall risk of infections and is associated with a reduced risk of bacterial and non-herpetic skin infections compared with placebo, resulting in a reduced need for anti-infective medication.Trial RegistrationThe trial was registered with ClinicalTrials.gov with ID number NCT03346434 on November 17, 2017.Infographic
Source: Pediatric Drugs - Category: Pediatrics Source Type: research